Summary:The anticonvulsant and motor effects of gabapentin (GBP) were evaluated in rat pups aged 16-17 days. Fourteen-day-old rat pups received an implanted stimulating electrode in the amygdala unilaterally. Kindled seizures were produced on day 16 of life by repeatedly applying an electrical current stimulus to the amygdala electrode. Animals received kindling stimulation until they achieved three consecutive generalized convulsions. On day 17, rat pups received one of four doses of GBP 10, 25, 50, or 100 mg/kg. After receiving GBP, rat pups again received electrical stimulation to the amygdala electrode to determine the extent to which GBP prevented the kindled seizure. Anticonvulsant effects were found at doses as low as 10 mg/kg. A separate group of naïve rats received GBP to determine the motor effects of each treatment dose. Impaired motor performance, quantified as time on a balance beam, occurred at doses of Ն50 mg/kg. In summary, our data indicate that in immature rats, GBP exerts an anticonvulsant effect against kindled seizures at doses that do not significantly impair motor performance. Key Words: GabapentinKindling-Amygdala.Gabapentin (GBP) is a widely used anticonvulsant medication approved for use in the United States as an adjunctive treatment of partial seizures with or without secondary generalization in patients older than 12 years. There are studies documenting and characterizing the efficacy of GBP against focal epilepsy in adult humans (1) and in animal models of focal seizures (2,3, and C. Taylor, personal communication). By comparison, relatively few clinical studies (4-8) and only one laboratory study (9) examined the effects of GBP in children younger than 12 years or in developing rats, respectively. We undertook to study the effects of GBP in an animal model of childhood temporal lobe epilepsy. We have previously modeled childhood temporal lobe epilepsy using developing rats exposed to amygdala kindling by repetitive electrical stimulation (10-12).In adult rats, GBP is effective against kindled hippocampal or amygdala seizures. Doses of 10-25 mg/kg subcutaneously or intraperitoneally correspond approximately to the typical doses used in humans. At doses of Ն10-30 mg/kg, GBP prevented or attenuated seizure propagation and generalization, as measured by improvement in the behavioral seizure score (2, and C. Taylor, personal communication). Suppression of epileptic activity within the hippocampus was seen only at doses higher than the minimal dose required to suppress seizure propagation. Only at higher doses did GBP suppress kindled epileptic activity within the hippocampus in adult rats. GBP doses >30 mg/kg were necessary to shorten the afterdischarge in the hippocampus. A dose of 300 mg/kg was required to increase the afterdischarge threshold. To date, GBP has not been tested against kindled seizures in developing rats. In this study, we report the anticonvulsant effects of GBP against kindled seizures in P15-P17 rat pups.
METHODSSprague-Dawley albino rat pups (Charles River Laborato...